CoChat

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

Open access
Seaquist, Elizabeth R., Dulude, Hélène, Zhang, Xiaotian M., Rabasa‐Lhoret, Remi, Tsoukas, George M., Conway, James R., Weisnagel, Stanley J., Gerety, Gregg, Woo, Vincent C., Zhang, Shuyu, Carballo, Dolorès, Pradhan, Sheetal, Piché, Claude A., Guzman, Cristina B. · 2018 · Diabetes, Obesity and Metabolism
Cited by 54

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

In the present multicentre, open‐label, prospective, phase III study, we evaluated the real‐world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D). Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time. Questionnaires were used to collect information about adverse events and ease of use of NG. In the efficacy analysis population, 69 patients experienced 157 HEs. In 95.7% patients, HEs resolved within 30 minutes of NG administration. In all the 12 severe HEs, patients awakened or returned to normal status within 15 minutes of NG administration without additional external medical help. Most caregivers reported that NG was easy to use. Most adverse events were local and of low to moderate severity. In this study, a single, 3‐mg dose of NG demonstrated real‐life effectiveness in treating moderate and severe HEs in adults with T1D. NG was well tolerated and easy to use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13278

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 54

Metadata

Authors
Seaquist, E. R., Dulude, H., Zhang, X. M., Rabasa‐Lhoret, R., Tsoukas, G. M., Conway, J. R., Weisnagel, S. J., Gerety, G., Woo, V. C., Zhang, S., Carballo, D., Pradhan, S., Piché, C. A., & Guzman, C. B.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-03-22
Volume
20
Issue
5
Pages
1316-1320
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2789501252
Cited by
54
References
7
FWCI
5.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting. https://app.cochat.ai/papers/10.1111/dom.13278
The paper
Seaquist, E. R., Dulude, H., Zhang, X. M., Rabasa‐Lhoret, R., Tsoukas, G. M., Conway, J. R., Weisnagel, S. J., Gerety, G., Woo, V. C., Zhang, S., Carballo, D., Pradhan, S., Piché, C. A., & Guzman, C. B. (2018). Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13278

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.